

1991

Methylene Blue as an Inhibitor of Superoxide Generation by Xanthene Oxidase: A Potential New Drug for the Attenuation of Ischemia/Reperfusion Injury

Steven C. Salaris

Charles F. Babbs

Purdue University, babbs@purdue.edu

William D. Voorhees

Follow this and additional works at: <http://docs.lib.purdue.edu/bmepubs>

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Salaris, Steven C.; Babbs, Charles F.; and Voorhees, William D., "Methylene Blue as an Inhibitor of Superoxide Generation by Xanthene Oxidase: A Potential New Drug for the Attenuation of Ischemia/Reperfusion Injury" (1991). *Weldon School of Biomedical Engineering Faculty Publications*. Paper 91.

<http://docs.lib.purdue.edu/bmepubs/91>

METHYLENE BLUE AS AN INHIBITOR OF SUPEROXIDE GENERATION BY XANTHINE OXIDASE:

A POTENTIAL NEW DRUG FOR THE ATTENUATION OF ISCHEMIA/REPERFUSION INJURY

STEVEN C. SALARIS, CHARLES F. BARBS, and WILLIAM D. VOORHEES III

Biomedical Engineering Center, and School of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.

[Biochemical Pharmacology, Vol. 42, No. 3, pp. 499-506, 1991]

ABSTRACT

Tissue oxidases, especially xanthine oxidase, have been proposed as primary sources of toxic oxygen radicals in many experimental models of disease states. Among these, ischemia-reperfusion injury may be of the greatest clinical interest. In this paper we propose the use of methylene blue as a means of suppressing the production of superoxide radicals, O_2^- , by acting as an alternative electron acceptor for xanthine oxidase. Previous work has indicated that methylene blue accepts electrons from xanthine oxidase at the iron-sulfur center. Initial experiments in our laboratory demonstrated that (1) pairs of electrons from each enzymatic oxidation are transferred to methylene blue, (2) the reduction of methylene blue can be achieved by model iron-sulfur centers, similar to the iron-sulfur center of xanthine oxidase, (3) reduced methylene blue auto-oxidizes to produce H_2O_2 directly, rather than O_2^- , and (4) methylene blue is effective at non-toxic levels (2-5 mg/kg) in preventing free radical damage to liver and kidney tissues in an in vitro model of ischemia and reoxygenation. Accordingly, we propose that methylene blue may represent a new class of antioxidant drugs that competitively inhibit reduction of molecular oxygen to superoxide by acting as alternative electron acceptors for tissue oxidases. We have termed these agents "parasitic" electron acceptors.

Key words: class, drug development, hydrogen peroxide, new, novel, oxidative stress, reactive oxygen species, therapy


Abbreviations: DMSA, dimercaptosuccinic acid; $HO\cdot$, hydroxyl radical; HX, hypoxanthine; LD50, median lethal dose; MDA-LM, malondialdehyde-like materials; NBT, nitroblue tetrazolium; SOD, superoxide dismutase; and X, xanthine.

Supported by Grants HL-36712 and HL-35996 from the National Heart, Lung, and Blood Institute, U.S. Public Health Service, Bethesda, Maryland, USA.

INTRODUCTION

An increasing body of evidence implicates the involvement of oxygen-derived free radicals in the pathophysiology of arthritis, iron toxicity, Parkinson's disease, and a variety of disease states including ischemia followed by reperfusion [1-4]. Superoxide (O_2^-) is undoubtedly the most abundant oxygen radical generated in vivo. Biological sources of superoxide include activated leukocytes [5], the mitochondrial electron transport chain [6], and tissue oxidases, most notably xanthine oxidase [7-9]. The current model of reperfusion injury [1, 7, 10, 11] states that during the ischemic period, hypoxanthine and xanthine substrates accumulate due to the anaerobic breakdown of ATP. At the same time, there is a measurable increase in the amount of xanthine oxidase in the cell due to a proteolytic conversion of xanthine dehydrogenase to xanthine oxidase [12, 13]. Upon reoxygenation, a burst of superoxide radicals may be formed in certain cell types by the action of xanthine oxidase upon accumulated hypoxanthine and xanthine substrates [7].

In the presence of suitably chelated iron, a fraction of the superoxide generated by biological sources may participate in the superoxide driven Fenton reaction, in which hydroxyl radical ($HO\cdot$) formation occurs [4, 14, 15]:



where A^{-n} is a chelator anion rendering iron soluble at physiological pH. Nascent hydroxyl radicals, or perhaps intermediate oxo-iron complexes themselves [16, 17], can react with various proteins, nucleic acids or lipids in the cell [4, 18, 19], initiating chains of uncontrolled free radical reactions that may complicate circulatory shock, arterial thromboembolism, cardiac arrest, and other clinical entities.

There are currently several methods under investigation to prevent or attenuate superoxide and iron mediated injury. The first is the use of antioxidant enzymes such as superoxide dismutase (SOD) and catalase which scavenge and break down superoxide and hydrogen peroxide, respectively [20, 21]. Alternatively, iron chelating compounds such as deferoxamine may inhibit superoxide-initiated injury, presumably by preventing the redox cycling of iron [22, 23]. Another attractive approach may be the use of xanthine oxidase inhibitors [2, 24, 25]. Best known among these inhibitors are the purine analogs, oxypurinol and allopurinol, which bind competitively to the purine binding site of the enzyme, displacing hypoxanthine and xanthine.

However, another neglected approach to pharmacologic inhibition of O_2^- production by xanthine oxidase exists. In 1988, Kelner et al. [26] re-examined the early work of McCord and Fridovich [27] suggesting that methylene blue can act as a willing electron acceptor for xanthine oxidase, an enzyme that allows for the anaerobic oxidation of purine substrates. They proposed that this readily available and already clinically used compound might inhibit the production of superoxide in postischemic tissues [26] by competing with molecular oxygen at the iron-sulfur

centers of xanthine oxidase. Intrigued by Kelner's thoughts and observations, we have begun to study methylene blue as a possible inhibitor of O_2^- production by xanthine oxidase.

In this paper, we present an elaboration of Kelner's original idea concerning the mechanism of action and pharmacology of methylene blue during oxidative stress. We propose that methylene blue (and perhaps other related compounds) may attenuate the pathophysiology of reperfusion injury by two methods: First, if given as a pretreatment (prior to ischemia), it may allow for the anaerobic breakdown of hypoxanthine and xanthine to uric acid and thus attenuate the accumulation of hypoxanthine during ischemia. Second, if given either before ischemia or just before reperfusion, methylene blue may help prevent superoxide formation, since it competes favorably with molecular oxygen for reduction by xanthine oxidase [28]. In this hypothetical role, methylene blue does not act as a classical xanthine oxidase inhibitor, because it does not slow the rate of oxidation of hypoxanthine or xanthine. Indeed, it appears to increase the rate of such reactions in some studies [28]. Instead, methylene blue acts as an inhibitor of oxygen reduction, and may well function as such for other oxidases in addition to xanthine oxidase.

Routine use of methylene blue as a tissue stain leaves little doubt as to its ability to penetrate intracellular as well as extracellular fluid compartments. Note however, that the doses required to achieve the desired therapeutic effect are insufficient to render an animal or patient comically blue in color (pseudocyanosis) and indeed are within the range currently recommended for use in human medicine.

Biochemically, our working hypothesis is that methylene blue is reduced to the colorless leuko form, as a result of the action of xanthine oxidase. In the presence of oxygen, the leukomethylene blue then auto-oxidizes back to ordinary methylene blue with the concurrent formation of hydrogen peroxide directly, rather than superoxide. The transfer of electrons in pairs to methylene blue, rather than singly to oxygen, thus short-circuits the formation of superoxide by the enzyme. Without superoxide, the reduction of Fe^{3+} to Fe^{2+} does not occur, and even though hydrogen peroxide is formed, there is not sufficient Fe^{2+} to allow for either the formation of damaging amounts of $HO\cdot$ by Fenton's reaction or the formation of ferrous-ferric complexes capable of initiating lipid peroxidation in the absence of $HO\cdot$ [16, 17]. The hydrogen peroxide that is formed is then readily detoxified in vivo by the action of catalase and peroxidases.

Regarding the products of auto-oxidation of leukomethylene blue, there appear to be two schools of thought, one stating that leukomethylene blue auto-oxidizes to hydrogen peroxide [26, 29] and another stating that leukomethylene blue can auto-oxidize univalently to superoxide [27]. Accordingly, we were especially interested in exploring the major products of leukomethylene blue auto-oxidation. Significant univalent reduction of oxygen by leukomethylene blue to form superoxide would obviate the use of methylene blue to suppress superoxide formation.

For these reasons, we gave serious consideration to the potential use of methylene blue as a drug to suppress superoxide formation by xanthine oxidase and performed a number of simple biochemical experiments to (1) explore the number of electrons transferred during methylene blue reduction, (2) determine if model iron-sulfur centers could reduce methylene blue, (3)

measure superoxide production during auto-oxidation of leukomethylene blue, and (4) test the ability of methylene blue to suppress one indicator of oxygen radical injury in a tissue model of ischemia and reperfusion.

METHODS AND RESULTS

Stoichiometry of methylene blue reduction

To further explore the antioxidant potential of methylene blue in the laboratory, we first studied the stoichiometry of electron transfer from xanthine to methylene blue. Others have suggested that for each oxidation step, either from hypoxanthine to xanthine or from xanthine to uric acid, there are two electrons transferred to the enzyme [8, 30]. If, in turn, xanthine oxidase transfers two electrons to methylene blue in each oxidation step, we expect 1 mole of leukomethylene blue to be produced for each mole of xanthine oxidized to uric acid and 2 moles of leukomethylene blue for each mole of hypoxanthine oxidized completely to uric acid.

To test this assertion, we performed some simple spectrophotometric studies. A reaction mixture of 0.05 units/ml of xanthine oxidase was added to a 1.5-mL quartz spectrophotometric cuvet containing 37.4 nmol of methylene blue, and 15 nmol of either xanthine or hypoxanthine in argon-saturated (anoxic) Tris-Ringer buffer* at pH 7.4. The reaction vessel was suffused with argon and covered to exclude oxygen. The conversion of methylene blue to leukomethylene blue was recorded as a decrease in the absorbance of the solution at 667 nm. Based on the extinction coefficient of methylene blue in Tris-buffer ($4.9 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$, our value), the amount of methylene blue reduced was calculated. Our measured coefficient is in good agreement with the literature value ($50,119 \text{ M}^{-1} \text{ cm}^{-1}$) [31]. The results (Table 1) indicated that xanthine oxidase supplied with 15 nmol of xanthine reduced 14.6 ± 0.3 nmol of methylene blue (mean \pm SEM) and 15 nmol of hypoxanthine reduced 29.1 ± 0.4 nmol of methylene blue (N = 10).

These observations confirm that the reduction of methylene blue is a 2-electron process as previously indicated by Blaedel and Meloche [32]. This observation is important, because if leukomethylene blue is a 2-electron reduction product of methylene blue, then it is reasonable to expect that two electrons might also be transferred to molecular oxygen when methylene blue auto-oxidizes, thus forming H_2O_2 rather than superoxide, as proposed previously by Kelner et al. [26].

* The Tris-Ringer buffer solution included 4.0 mM KCl, 100 mM NaCl, 2.0 mM CaCl_2 , 40 mM Tris, and 200 mg/dL glucose, pH 7.4. Tris was chosen as a buffer rather phosphate because of its solubility in the presence of calcium.

Table 1. Methylene blue reduction by xanthine oxidase under anaerobic conditions. The substrate was either xanthine (X, 15 nmol) or hypoxanthine (HX, 15 nmol)

Substrate	Change in absorbance	Methylene blue reduced (nmol)	
		Observed	Observed/Expected
X	0.411	12.5	0.833
X	0.482	14.7	0.980
X	0.472	14.4	0.960
X	0.501	15.3	1.020
X	0.475	14.5	0.967
X	0.494	15.0	1.000
X	0.502	15.3	1.020
X	0.490	14.9	0.993
X	0.464	14.1	0.940
X	0.521	15.9	1.060
HX	0.940	28.7	0.957
HX	0.945	28.8	0.960
HX	0.984	30.0	1.000
HX	0.919	28.0	0.933
HX	0.913	27.8	0.927
HX	0.979	29.9	0.997
HX	1.029	31.4	1.047
HX	0.974	29.7	0.990
HX	0.894	27.3	0.910
HX	0.975	29.7	0.990

Reaction of model iron-sulfur centers with methylene blue

The reduction of methylene blue by xanthine oxidase occurs in both the molybdenum free and deflavinated enzyme forms [33, 34]. Therefore, it has been suggested that the point of methylene blue reduction must be at the iron-sulfur center [26]. The native xanthine oxidase enzyme contains two iron-sulfur centers of the 2Fe-2S type [8, 35], having two iron atoms chelated by six sulfur moieties (Fig. 1).

XANTHINE OXIDASE




Fig. 1. Cartoon-like sketch of xanthine oxidase, illustrating the proposed role of methylene blue (MB) as a parasitic electron acceptor. The enzyme consists of two subunits, each with purine binding sites, Mo^{IV} , iron-sulfur (Fe-S) centers, and a flavin [8, 35-37]. The catalytic action is illustrated with molecular oxygen (left) and methylene blue (right) serving as electron acceptors. In the normal sequence on the left, electrons travel to the flavin to be transferred to oxygen, forming superoxide [36, 37]. The authors propose that in the presence of methylene blue, on the right, the electrons are diverted to the dye at the iron-sulfur center. In this way, methylene blue may act as a parasitic electron acceptor that inhibits production of O_2^- .

To further explore this concept, we sought to determine if a reduced iron-sulfur center can, in fact, reduce methylene blue. In simple aqueous solutions, ferrous iron alone did not reduce methylene blue and neither did thiols. Hence, the juxtaposition of iron and sulfur atoms of the iron-sulfur center must be critical. To model a reduced iron-sulfur center, we utilized the chelate of Fe^{2+} and an excess of dimercaptosuccinic acid (DMSA) in dilute, anoxic (argon saturated) solutions. The combination of these reagents caused an evident interaction between the ferrous iron and the sulfur groups of DMSA, which formed a colored chelate that ranges from brown to pink, depending on the relative concentrations of the two compounds, and was not formed upon combination of ferrous iron with ordinary succinic acid. This model is less complex than the true structure of the iron-sulfur center, but it still includes an Fe^{2+} surrounded by at least four sulfurs (Fig. 2).

IRON SULFUR CENTER MODEL




Fig. 2. An idealized configuration of the DMSA-iron chelate. The Fe^{2+} is chelated by the four sulfhydryl groups of two dimercaptosuccinic acid molecules. This complex models the iron:sulfur ratio seen in the iron-sulfur centers of xanthine oxidase and appears to mimic the iron-sulfur center of xanthine oxidase in that it is capable of reducing methylene blue.

These experiments used 50 nmol/mL of Fe^{2+} chelated in the presence of 800 nmol/mL of DMSA. At the above concentrations, the chelate formed was pink in color and exhibited an absorbance peak at 360 nm. DMSA (from Aldrich) and 50 nmol of FeSO_4 were added to argon-saturated (anoxic) Tris-Ringer buffer (1.0 mL, pH 7.4), after which 15 nmol of methylene blue was added.

In $N = 6$ trials, the absorbance of the methylene blue (667 nm) was seen to decrease after only 3 min (Fig. 3). The cuvet was then reoxygenated by gently bubbling with 100% O_2 to promote the auto-oxidation of leukomethylene blue with return of the original color. DMSA-only and Fe^{2+} -only controls did not reduce methylene blue ($N = 3$). These simple experiments are consistent with the hypothesis that reduced iron-sulfur centers, similar to those in xanthine oxidase, can, in fact, reduce methylene blue.




Fig. 3. Typical visible spectra illustrating methylene blue reduction in the presence of the model iron-sulfur (Fe-S) center. (1) A 6 μM concentration of methylene blue (MB) showed characteristic absorbance peak at 667 nm. (2) After 3 min, the methylene blue absorbance peak was reduced anaerobically in the presence of the model Fe-S centers (50 μM FeSO_4 + 800 μM DMSA). (3) When this mixture was reoxygenated, the leucomethylene blue auto-oxidized and the original blue color returned. (4) The spectrum of the chelate alone is included for comparison. Spectra were manually digitized for plotting. FeSO_4 alone and DMSA alone did not reduce methylene blue (data not shown).

Auto-oxidation of leukomethylene blue

To more directly test the hypothesis that methylene blue auto-oxidation yields H_2O_2 rather than O_2^- , we compared auto-oxidation of Fe^{2+} -citrate with that of leukomethylene blue. Ferrous-citrate is expected to auto-oxidize via a single electron transfer, Fe^{2+} -citrate + $\text{O}_2 \rightarrow \text{Fe}^{3+}$ -citrate + O_2^-) thus providing a positive control. Fe^{2+} -citrate (500 μM) was added to an O_2 bubbled solution of pH 7.4 Tris buffer. To detect O_2^- , nitroblue tetrazolium (NBT, 500 μM) was added at 0, 15, 30, 45, 60, or 90 sec after Fe^{2+} -citrate oxidation had begun and allowed to react for 3 min at room temperature. In the presence of O_2^- NBT is reduced to a purple diformazan, which can be extracted into toluene and measured spectrophotometrically [38]. This approach was selected as an alternative to cytochrome-c reduction for the present application, because the leuco-dyes as well as O_2^- , are known to reduce cytochrome-c [27].

In a similar fashion, methylene blue (250 μM) was reduced to leukomethylene blue by addition of equimolar amounts of sodium hydrosulfite at pH 7.4. The solution was then reoxygenated until the blue color completely returned (approximately 10 sec), after which NBT was added at similar times as above. In some experiments, the NBT was added into the leukomethylene blue at time 0 and the solution then reoxygenated. Parallel control experiments were performed in the presence of 2 mg/mL (6000 units/ml) superoxide dismutase from Sigma (N = 3).

The reduced NBT from the auto-oxidation experiments was then extracted into 3 vol. of toluene and read in a spectrophotometer ($\lambda_{\text{max}} = 595 \text{ nm}$) against a toluene blank. Based on the extinction coefficient of reduced NBT in toluene (our value $5.36 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$), the concentration of reduced NBT was calculated by Beer's Law. Results of such time course experiments comparing auto-oxidation of Fe^{2+} -citrate and leukomethylene blue are shown in Fig. 4.

The left panel of Fig. 4 illustrates the SOD inhibitable reduction of NBT following auto-oxidation of Fe^{2+} -citrate during the first 150 sec. The decrease in colored diformazan formation with later addition of NBT reflects the spontaneous dismutation of O_2^- to H_2O_2 . In comparison, the right panel of Fig. 4 shows negligible amounts of SOD inhibitable NBT reduction following auto-oxidation of leukomethylene blue during the first 150 sec. NBT reduction at time 0 is attributable to the direct action of leukomethylene blue in the absence of oxygen, which was not SOD inhibitable. These observations are consistent with the hypothesis that molecular oxygen reacting with leukomethylene blue in buffered, neutral aqueous solution is not reduced to superoxide, but probably undergoes a direct 2-electron reduction to H_2O_2 .




Fig. 4. Left panel: Appearance of SOD inhibitable NBT reducing equivalents after auto-oxidation of 500 μM Fe^{2+} -citrate in pH 7.4 Tris buffer. Auto-oxidation began at time zero. NBT (500 μM) was added at the times indicated, and reduced NBT was recovered by toluene extraction and measured spectrophotometrically. The NBT reducing equivalents detected decayed exponentially over time as would be expected for superoxide undergoing spontaneous dismutation. Addition of Sigma SOD (6000 units/mL) completely quenched NBT reduction by this system. This experiment constitutes a positive control since auto-oxidation of ferrous iron chelates is well known to produce superoxide. Values are means \pm SEM for $N = 3$. Right panel: Appearance of NBT reducing equivalents after auto-oxidation of leukomethylene blue. This series of experiments was similar to the series in the left panel. Leukomethylene blue was produced by the addition of 250 μM sodium hydrosulfite to an equimolar amount of methylene blue under anaerobic conditions. The solution was then bubbled with 100% oxygen to initiate auto-oxidation of leukomethylene blue. NBT (500 μM) was added at the times indicated, and reduced NBT, recovered by toluene extraction, was measured spectrophotometrically. When NBT was added directly to leukomethylene blue, there was reduction of NBT before addition of oxygen that was not SOD inhibitable. There was no SOD inhibitable NBT reduction after oxidation. Values are means \pm SEM for $N = 3$.

Inhibition of reoxygenation injury in tissue slices

To test the ability of methylene blue to quench free radical formation in ischemia/reperfusion, we employed a previously described model of ischemia and reoxygenation [39, 40] *in vitro*, in which free floating liver or kidney slices were exposed to 60 min of ischemia in argon-saturated (anoxic) buffer before being treated with methylene blue at final concentrations of 0, 1, 2, 5, 10 or 25 $\mu\text{g/mL}$ (mg/kg) 10 min prior to reoxygenation. The tissues were then reoxygenated in 100% O_2 saturated buffer for 60 min, after which the tissues and buffer were assayed, using the thiobarbituric acid reaction [41] for malondialdehyde-like materials (MDA-LM), which are indicators of free radical mediated lipid peroxidation. The results (Figs. 5 and 6) show that significant production of MDA-LM occurred at zero or low concentrations of methylene blue. However, significant concentration-related attenuation of MDA-LM generation occurred for both tissues.




Fig. 5. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat kidney slices in the presence of various concentrations of methylene blue. Methylene blue was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr total. Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like materials measured by the thiobarbituric acid method are shown \pm SEM. An asterisk (*) indicates significance vs. untreated controls at $\alpha = 0.05$ by Scheffe's multiple comparison test. Values are means \pm SEM for $N = 6$.





Fig. 6. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat liver slices in the presence of various concentrations of methylene blue. Methylene blue was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr total. Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like materials measured by the thiobarbituric acid method are shown \pm SEM. An asterisk (*) indicates significance vs. untreated controls at $\alpha = 0.05$ by Scheffe's multiple comparison est. Values are means \pm SEM for $N = 6$.

Methylene blue alone did not inhibit the thiobarbituric acid reaction, as was determined by adding various methylene blue concentrations to MDA standards and observing no inhibition of reaction product formation. These data confirm those previously published [39] and suggest that clinically realistic doses (5 mg/kg) of methylene blue can protect against oxygen radical mediated injury of postischemic tissues.


DISCUSSION

The foregoing simple experiments support the claim that methylene blue may well be an effective antioxidant in the setting of ischemia/reperfusion injury when administered in clinically realistic concentrations prior to the return of molecular oxygen. Methylene blue, together with other related compounds such as celestine blue, toluidine blue O, thionin, and azure A, which are also reduced to leuko forms by xanthine oxidase (unpublished observations) [42], may constitute a new class of antioxidant drugs that act by suppressing O_2^- formation by tissue oxidases. In contrast to classical purine analog type xanthine oxidase inhibitors, these agents would not inhibit hypoxanthine and xanthine conversion to uric acid, but would selectively inhibit O_2^- formation by serving as competitive, alternative co-substrates.

Such alternative electron acceptors seem to be characterized by their apparent ability to accept two electrons, rather than one electron, and, in turn, auto-oxidizing to form H_2O_2 directly rather than O_2^- . That is



rather than



The high affinity of methylene blue for the iron-sulfur center of xanthine oxidase [28] favors the former over the latter sequence, even in the presence of 100% O₂ during reoxygenation. In this sense, we argue that methylene blue acts as a “parasitic” electron acceptor, shunting electron flow from the normal pathway within the enzyme to form leukomethylene blue at the level of the iron-sulfur centers (Fig. 1, right). The drug effectively short-circuits O₂⁻ generation since the electron flow through the enzyme is preferentially routed to methylene blue at the iron-sulfur center rather than to molecular oxygen at the flavin centers. In turn, redox cycling of low molecular weight chelate iron in the superoxide driven Fenton reaction is avoided, because there is no superoxide to reduce Fe³⁺ to Fe²⁺.

Although earlier work by McCord and Fridovich [27] indicated that reduced methylene blue was capable of univalently reducing oxygen to superoxide, the detection method used (adenochrome formation) indicated that the rate of superoxide formation was relatively slow. The present results clearly indicate that the formation of hydrogen peroxide, rather than superoxide, is the dominant product of leukomethylene blue auto-oxidation, compared to ferrous citrate auto-oxidation, in which abundant superoxide is formed. The end result, prevention of O₂⁻ generation, is similar to the effect of SOD. However, unlike SOD, methylene blue, which is a low molecular weight, partially liposoluble agent, is unquestionably able to penetrate cells and tissues, in view of its use as a rapidly penetrating histological stain. These properties may make methylene blue an especially useful pharmacologic agent, which has already been proven safe at likely effective doses in human patients.

Methylene blue is currently used in medicine for the treatment of cyanide poisoning, methemoglobinemia, nitrite poisoning, and urinary tract infections [43-47]. In a guinea pig model of nitrite toxicosis, 10 mg/kg of methylene blue protected against methemoglobinemia following a 50 mg/kg dose of NaNO₂ [47]. As early as 1935, methylene blue was used as a treatment for urinary tuberculosis [44]. The treated human patients showed post-operative weight increase and relief of symptoms in 11 of 12 cases with unilateral renal tuberculosis. In the case of methemoglobinemia in the adult human, methylene blue is given as an injection of 50 mL of a 1% solution. The dye then acts therapeutically to accelerate reductive processes in the cell. It is effective in cases of NADPH-methemoglobin reductase deficiency but not in cases of methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency [46, 48]. It is also a relatively non-toxic compound and can be used over a wide range of doses. In humans with cyanide poisoning, a 500 mg bolus is given, which corresponds to a dose of approximately 7 mg/kg [49]. In the dog and rat, the LD50 values (median lethal dose) for i.v. methylene blue are 50 and 1250 mg/kg, respectively. In monkeys, the lowest published toxic dose is 10 mg/kg [50].

The action of methylene blue and similar drugs as parasitic electron acceptors opens up a variety of therapeutic possibilities. As a pretreatment, as in cases of aortic cross-clamping or organ transplantation, methylene blue might be given just prior to the ischemic period to provide a substrate for the anaerobic breakdown of hypoxanthine and xanthine. In conditions such as circulatory shock, arterial thromboembolism, or bowel torsion with strangulation, methylene blue could be given as a post-treatment (i.e. after the onset of ischemia) and still be effective, since the competition kinetics favor the reduction of methylene blue rather than molecular

oxygen [28]. The low-toxicity, effectiveness, and unique biochemistry of methylene blue and its congeners, may make such compounds valuable in the future study and treatment of tissue injury thought to be mediated by xanthine oxidase and superoxide.

REFERENCES

1. Saugstad OD, Hallman M, Abraham JL, Epstein B, Cochrane C and Gluck L, Hypoxanthine and oxygen induced lung injury: A possible basic mechanism of tissue damage? *Pediatr Res* 18: 501-504, 1984.
2. Koyama I, Bulkley GB, Williams GM and Im MJ, The role of oxygen free radicals in mediating the reperfusion injury of cold-preserved ischemic kidneys. *Transplantation* 40: 590-595, 1985.
3. Thurman RG, Marzi I, Seitz G, Thies J, Lemasters JJ and Zimmerman F, Hepatic reperfusion injury following orthotopic liver transplantation in the rat. *Transplantation* 46: 502-506, 1988.
4. Deby C and Goutier R, New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. *Biochem Pharmacol* 39: 399- 405, 1990.
5. Markert M, Andrews PC and Babior BM, Measurement of O_2^- production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. *Methods Enzymol* 105: 358-365, 1984.
6. Boveris A and Chance B, The mitochondrial generation of hydrogen peroxide (general properties and effect of hyperbaric oxygen). *Biochem J* 134: 707-716, 1973.
7. McCord JM, Oxygen-derived free radicals in postischemic tissue injury. *New Engl J Med* 312: 159-163, 1985.
8. Walsh C, *Enzymatic Reaction Mechanisms*, W. H. Freeman & Co., San Francisco, 1979.
9. Parks DA and Granger DN, Xanthine oxidase: Biochemistry, distribution, and physiology. *Acta Physiol Stand [Suppl]* 548: 87-99, 1986.
10. Freeman BA and Crapo JD, Biology of disease--Free radicals and tissue injury. *Lab Invest* 47: 412-426, 1982.
11. Babbs CF, Reperfusion injury of postischemic tissues. *Arm Emerg Med* 17: 1148-1157, 1988.
12. Al-Khalidi UAS and Chaglassian TH, The species distribution of xanthine oxidase. *Biochem J* 97: 318-320, 1965.

13. Stirpe F and Della Corte E, The regulation of rat liver xanthine oxidase: Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). *J Biol Chem* 244: 3855-3863, 1969.
14. Babbs CF, Role of iron ions in the genesis of reperfusion injury following successful cardiopulmonary resuscitation: Preliminary data and a biochemical hypothesis. *Ann Emerg Med* 14: 777-783, 1985.
15. Aust SD, Morehouse LA and Thomas CE, Hypothesis paper--Role of metals in oxygen radical reactions. *J Free Radic Biol Med* 1: 3-25, 1985.
16. Bucher JR, Tien M and Aust SD, The requirement for ferric in the initiation of lipid peroxidation by chelate ferrous iron. *Biochem Biophys Res Commun* 111: 777-784, 1983.
17. Minotti G and Aust SD, The requirement for iron(III) in the initiation of lipid peroxidation of iron(II) and hydrogen peroxide. *J Biol Chem* 262: 1098-1104, 1987.
18. Aust SD and Svingen BA, The role of iron in enzymatic lipid peroxidation. In: *Free Radicals in Biology* (Ed. Pryor W), Vol. V, pp. 1-28. Academic Press, New York, 1982.
19. Tien M, Svingen BA and Aust SD, An investigation into the role of hydroxyl radical in xanthine oxidase dependent lipid peroxidation. *Arch Biochem Biophys* 216: 142-151, 1982.
20. Kim M and Akera T, O₂ free radicals: Cause of ischemia-reperfusion injury to cardiac Na⁺-K⁺-ATPase. *Am J Physiol* 252: 252-257, 1987.
21. Schneider J, Frederichs E and Giertz H, Comparison of the protective effects by human and bovine superoxide dismutase against ischemia- and reperfusion-induced impairment of kidney function in anaesthetized rats. *Free Radic Biol Med* 3: 21-26, 1987.
22. Green CJ, Healing G, Simpkin S, Lunec J and Fuller BJ, Desferrioxamine reduces susceptibility to lipid peroxidation in rabbit kidneys subjected to warm ischaemia and reperfusion. *Comp Biochem Physiol* 85B: 113-117, 1986.
23. Badylak SF, Simmons A, Turek J and Babbs CF. Protection from reperfusion injury in the isolated rat heart by postischemic deferoxamine and oxypurinol administration. *Cardiovasc Res* 21: 500-506, 1987.
24. Raytch RE, Chuknyiska RS and Bulkley GB. The primary localization of free radical generation after anoxia/reoxygenation in isolated endothelial cells. *Surgery* 102: 121-131, 1987.
25. Badylak SF, Babbs CF, Kouaias C and Blaho K. Effect of allopurinol and dimethylsulfoxide on long-term survival in rats after cardiorespiratory arrest and resuscitation. *Am J Emerg Med* 4: 313-318, 1986.

26. Kelner MJ, Bagnell R, Hale B and Alexander NM. Potential of methylene blue to block oxygen radical generation in reperfusion injury. In: *Oxygen Radicals in Biology and Medicine* (Ed. von Sonntag C), pp. 895-898. Plenum Press, New York, 1988.
27. McCord JM and Fridovich I, The utility of superoxide dismutase in studying free radical reactions. II: The mechanism of the mediation of cytochrome-c reduction by a variety of electron carriers. *J Biol Chem* 245: 1374-1377, 1970.
28. Kelner MJ, Bagnell R. Hale B and Alexander NM, Methylene blue competes with paraquat for reduction by flavo-enzymes resulting in decreased superoxide production in the presence of heme proteins. *Arch Biochem Biophys* 262: 422-426, 1988.
29. Kelner MJ and Alexander NM. Methylene blue directly oxidizes glutathione without the intermediate formation of hydrogen peroxide. *J Biol Chem* 260: 15168-15171, 1985.
30. Bray RC, Molybdenum iron-sulfur flavin hydroxylases and related enzymes. In: *The Enzymes* (Ed. Boyer PD), Vol. XII, pp. 310-317. Academic Press, New York, 1970.
31. Grasseli J and Ritchey W (Eds.), *CRC Atlas of Spectral Data and Physical Constants for Organic Compounds*, Vol. 3, p. 611. CRC Press, Boca Raton, 1975.
32. Blaedel WJ and Meloche VW. *Elementary Quantitative Analysis: Theory and Practice*, 2nd Edn. Harper & Row, New York, 1963.
33. Gardlik S, Barber MJ and Rajagopalan KV, A molybdopterin-free form of xanthine oxidase. *Arch Biochem Biophys* 259: 363-371, 1987.
34. Kanda M, Bray O, Rajagopalan KV and Handler P, Studies on the dissociation of flavin adenine dinucleotide from metalloflavoproteins. *J Biol Chem* 247: 765-770, 1971.
35. Bray RC, The flavin and the other catalytic and redox centers of xanthine oxidase and related enzymes. In: *Flavins and Flavoproteins: Proceedings of the Seventh International Symposium of Flavins and Flavoproteins* (Ed. Williams CH), pp. 775-785. Elsevier/North Holland, New York, 1982.
36. Olson JS, Ballou DP, Palmer G and Massey V, The mechanism of action of xanthine oxidase. *J Biol Chem* 249: 4363-4382, 1974.
37. Massey V, Strickland S, Mayhew SG, Howell LG, Engel PC, Matthews RG, Schuman M and Sullivan PA, The production of superoxide anion radicals in the reaction of reduced flavins and flavoproteins with molecular oxygen. *Biochem Biophys Res Commun* 36: 891-897, 1969.
38. Auclair C and Voisin E, Nitroblue tetrazolium reduction. In: *Handbook of Methods for Oxygen Radical Research* (Ed. Greenwald RA), pp. 123-132. CRC Press, Boca Raton, 1985.

39. Salaris SC and Babbs CF, A rapid, widely applicable screen for drugs that suppress free radical formation in ischemia/reperfusion. *J Pharmacol Methods* 20: 335- 345, 1988.
40. Salaris SC and Babbs CF, The effect of oxygen concentration on the formation of malondialdehyde-like material in a model of tissue ischemia and reoxygenation. *Free Radic Biol Med* 7: 603-609, 1989.
41. Buege JA and Aust SD, Microsomal lipid peroxidation. *Methods Enzymol* 51: 302-310, 1978.
42. Kodama K. Studies on xanthine oxidase. VIII: The oxidation-reduction potential of the oxidase system. *Biochem J* 20: 1095-1103, 1926.
43. Nadler JE, Green H and Rosenbaum A, Intravenous injection of methylene blue in man with reference to its toxic symptoms and effect on the electrocardiogram. *Am J Med Sci* 188: 15-21, 1934.
44. Greenberg BE, Brodny ML, Davis TL and Armstrong C, Further studies of methylene blue in the treatment of urinary tuberculosis with presentation of a purified drug. *J Urol* 33: 168-178, 1935.
45. Macht DI and Harden WC, Toxicology and assay of methylene blue. *Ann Intern Med* 7: 738-745, 1933.
46. Smith RP and Thron CD. Hemoglobin. methylene blue and oxygen interactions in human red cells. *J Pharmacol Exp Ther* 183: 549-558, 1972.
47. Kociba RJ and Sleight SD, Nitride toxicosis in the ascorbic acid-deficient guinea pig. *Toxicol Appl Pharmacol* 16: 424-429, 1970.
48. Letchworth GJ, Bentinck-Smith J, Bolton GR, Wootton JF and Family L, Cyanosis and methemoglobinemia in two dogs due to a NADH methemoglobin reductase deficiency. *J Am Anim Hosp Assoc* 13: 75-79, 1977.
49. Windholz M, Budavari S, Blumetti RF and Otterbein ES (Eds.), *The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals*, 10th Edn. Merck & Co, Rahway, 1983.
50. Lewis RJ and Taktan RL (Eds.), *Registry of Toxic Effects of Chemical Substances: 1980. Vol. 2. v. 288*. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and National Institute for Occupational Safety and Health, Atlanta, February 1982.